CalciMedica (CALC) Non Operating Income (2022 - 2026)
CalciMedica's (CALC) quarterly Non Operating Income came in at $10.6 million in Q1 2026, up 627.63% YoY from $1.5 million in Q1 2025, and up 266.07% on a QoQ basis from -$6.4 million in Q4 2025.
CalciMedica (CALC) Non Operating Income (2022 - 2026) Analysis & Trends
CalciMedica (CALC) has 5 years of Non Operating Income data on file, last reported at $10.6 million in Q1 2026.
- Quarterly Non Operating Income rose 627.63% year-over-year to $10.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (down 55.61% YoY) and the FY2025 annual result came in at -$6.4 million, down 161.32% from the prior year.
- Non Operating Income climbed to $10.6 million in Q1 2026, from -$6.4 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $10.6 million in Q1 2026 to a low of -$6.4 million in Q4 2025.
- A 5-year average of $1.5 million and a median of $665000.0 in 2025 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2024 — Non Operating Income soared 1006.36% — and 2025, when it slumped 1952.54%.
- Tracing CALC's Non Operating Income over 5 years: stood at $4.5 million in 2022, then sank by 96.17% to $173000.0 in 2023, then soared by 1006.36% to $1.9 million in 2024, then slumped by 433.07% to -$6.4 million in 2025, then jumped by 266.07% to $10.6 million in 2026.
- The last three Non Operating Income figures came in at $10.6 million (Q1 2026), -$6.4 million (Q4 2025), and -$2.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | CalciMedica | 9.80 Mn | -8.82 Mn | - | -3.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.64 Mn |
| Mar 31, 2026 | 10.59 Mn |
| Dec 31, 2025 | -6.38 Mn |
| Sep 30, 2025 | -2.19 Mn |
| Jun 30, 2025 | 665,000.00 |
| Mar 31, 2025 | 1.46 Mn |
| Dec 31, 2024 | 1.91 Mn |
| Sep 30, 2024 | 118,000.00 |
| Jun 30, 2024 | 2.58 Mn |
| Mar 31, 2024 | 5.90 Mn |
| Dec 31, 2023 | 173,000.00 |
| Sep 30, 2023 | 214,000.00 |
| Jun 30, 2023 | 279,000.00 |
| Mar 31, 2023 | 3.05 Mn |
| Dec 31, 2022 | 4.52 Mn |
| Sep 30, 2022 | 707,000.00 |
| Jun 30, 2022 | 559,000.00 |
| Mar 31, 2022 | 581,000.00 |